ANRO
Alto Neuroscience, Inc.
NYSE · Healthcare · Biotechnology · US
$35.55
−2.34%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.67
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.65
- EPS estimate
- -$0.73
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +1.3%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $39
- PT range
- $26 – $55
- Analysts
- 3
2 Buy1 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026